Antibody-Drug Conjugates in Solid Tumors: From Magic Bullet to Standard of Care

Antibody-Drug Conjugates in Solid Tumors: From Magic Bullet to Standard of Care

Antibody-drug conjugates (ADCs) are rapidly transforming cancer treatment, evolving from a theoretical “magic bullet” into a standard of care across multiple solid tumors. By combining targeted antibodies with potent chemotherapy payloads, ADCs enhance treatment effectiveness while addressing long-standing limitations of traditional chemotherapy, including toxicity and diminishing efficacy over time.

Introduction: Why ADCs Matter Now

Antibody-drug conjugates (ADCs) have moved from a niche technology to a foundational class of cancer therapy in just over a decade. Today there are 12 ADCs approved across oncology globally, with more than 300 in active clinical development. The reason for this explosion is straightforward: ADCs are making chemotherapy more effective. They are doing so by addressing two of chemotherapy’s long-standing limitations—diminishing returns with each successive line of treatment, and cumulative toxicity that limits dose and duration.

Chemotherapy has saved more lives in the history of oncology than any other class of therapy. Yet sequential lines of single-agent chemotherapy in metastatic disease yield progressively shorter periods of disease control: seven months becomes five, then four, then three. ADCs were conceived to disrupt that arithmetic. The concept dates back to Paul Ehrlich’s “magic bullet” idea from 1913—a molecule that could selectively kill diseased cells while sparing healthy ones—but the technology required nearly a century to mature. The 2013 approval of T-DM1 (trastuzumab emtansine) for HER2-positive breast cancer marked the beginning of the modern ADC era. Since then, the technology has accelerated rapidly, expanding across breast, gastric, lung, urothelial, colorectal, gynecologic, and other tumor types.

Expert Analysis: How ADCs Work and Why They Keep Improving

ADC Architecture: Antibody, Linker, Payload

Every approved ADC shares the same architecture: a monoclonal antibody targeting a tumor-associated antigen, a cytotoxic payload (microtubule inhibitor, alkylator, or topoisomerase inhibitor), and a chemical linker. The linker is often overlooked but is critical—it determines where and how the payload is released.

Mechanism: More Than Targeted Delivery

The simple mental model—antibody finds tumor, drops chemo, kills cell—is incomplete. After injection, an ADC circulates as multiple species: intact ADC, free antibody, free payload, and partially deconjugated species. The payload’s half-life on the antibody is markedly longer than free payload alone (5–7 days versus a few hours), creating a prolonged low-dose chemotherapy effect. This is mechanistically similar to the rationale that made continuous-infusion 5-FU more effective than bolus 5-FU—you catch tumor cells across multiple cell-cycle phases. Targeted delivery and bystander effect (payload diffusing to neighboring cells regardless of antigen expression) add to this prolonged-exposure mechanism.

Importantly, this is also why ADCs still cause systemic side effects—nausea, fatigue, alopecia, neutropenia, interstitial lung disease (ILD)—despite the “targeted” framing. ADCs are not toxicity-free, and clinicians should not present them that way.

From T-DM1 to T-DXd: The Power of Re-engineering

T-DM1 paired trastuzumab with a microtubule inhibitor (DM1) via a non-cleavable linker, with three drug molecules per antibody. It was well tolerated and effective in HER2-positive metastatic breast cancer (~30% response rate, 6–7 months PFS), but it failed in gastric cancer (GATSBY), colorectal cancer (HERACLES), and HER2-low breast cancer.

Trastuzumab deruxtecan (T-DXd) keeps the same antibody but increases drug-to-antibody ratio (8:1), uses cysteine-specific linkage at the hinge region, and switches to a topoisomerase 1 inhibitor payload (deruxtecan). The result has been transformative. DESTINY-Breast01 enrolled patients with a median of six prior lines of therapy and produced a 20-month PFS—an unprecedented result in heavily pretreated metastatic disease. T-DXd is now approved in HER2-positive gastric cancer, HER2-low breast cancer (which represents more than half of metastatic breast cancer patients), HER2-mutant or HER2-overexpressing NSCLC, and—through DESTINY-PanTumor02—as a tumor-agnostic option for HER2 3+ tumors. Cervical, endometrial, ovarian, and biliary tract cancers all showed striking response rates in this trial.

Pushing ADCs Earlier in the Treatment Course

With response rates of 60% or more in the metastatic refractory setting, the next logical step is moving ADCs into earlier lines. T-DXd has now demonstrated benefit in the second-line metastatic (DESTINY-Breast03), first-line metastatic (DESTINY-Breast09, ~40-month PFS), and adjuvant (DESTINY-Breast05) settings, with neoadjuvant data showing unprecedented pathologic complete response rates. TROP2 ADCs (sacituzumab govitecan, datopotamab deruxtecan) are demonstrating activity in triple-negative and hormone receptor–positive breast cancer, with neoadjuvant and adjuvant trials reading out. The same trajectory is unfolding in lung, gastric, and urothelial cancers.

ADC + Immunotherapy: A Logical Combination

ADCs and immunotherapy are biologically complementary. Chemotherapy produces immunogenic cell death, and the ADC antibody itself can promote ADCC and dendritic cell maturation. Clinically, this synergy has produced striking results: BEGONIA (datopotamab deruxtecan plus durvalumab) yielded nearly 80% response rates in first-line triple-negative breast cancer; ASCENT-04 (sacituzumab govitecan plus pembrolizumab) showed approximately one-year PFS in PD-L1–positive triple-negative disease; EV-302 (enfortumab vedotin plus pembrolizumab in urothelial cancer) doubled overall survival compared with chemotherapy. The neoadjuvant urothelial trial of enfortumab vedotin plus pembrolizumab showed roughly 75% event-free survival at two years versus 40% with chemotherapy/observation.

Sequencing ADCs: An Emerging Challenge

As multiple ADCs become available—particularly in breast cancer—sequencing has become a real question. Retrospective Flatiron data published last year suggest that giving sacituzumab govitecan immediately after T-DXd yields only ~2.6 months PFS, whereas eribulin, capecitabine, or a taxane after T-DXd yields ~6 months. Prospective trials including TRADE-DXd (T-DXd vs. dato-DXd sequencing) and a study of sacituzumab govitecan plus trastuzumab after T-DXd in HER2-positive disease will help answer whether topo1-payload ADCs work after another topo1-payload ADC.

The Future: Smarter ADCs

Several frontiers are now being actively explored: bispecific ADCs (e.g., izolimab) targeting two epitopes for better internalization; dual-payload ADCs delivering complementary cytotoxic mechanisms; immune-stimulating antibody conjugates (ISACs) that deliver TLR or STING agonists; antibody-radio-conjugates; and probody-drug conjugates that mask the antibody until cleaved by tumor-microenvironment proteases. Payload-binding Fab fragments—designed to neutralize free payload in the systemic circulation while preserving tumor-localized activity—have shown encouraging preclinical data and represent a promising path to safer ADCs.

Better predictive biomarkers are also urgently needed. Immunohistochemistry alone has proven insufficient. Quantitative immunofluorescence assays (high-sensitivity HER2), reverse-phase protein arrays measuring both target expression and topo1, and molecular signatures like HER2DX are being evaluated to identify which patients benefit most. The ADC opportunity is now extending beyond oncology into immunology, neurology, and infectious disease.

Clinical Implications and Practice Takeaways

• ADCs are no longer a late-line rescue option—they are increasingly a frontline and curative-intent strategy.
• Set realistic expectations: ADCs cause meaningful toxicity (alopecia, nausea, neutropenia, ILD, neuropathy, dermatologic, ocular), and proactive management is essential.
• ILD/pneumonitis with T-DXd and other deruxtecan-based ADCs remains the most consequential safety issue—monitor pulmonary symptoms closely and intervene early.
• Tumor-agnostic T-DXd is FDA-approved for HER2 3+ tumors; consider HER2 IHC testing in patients with refractory solid tumors who have exhausted standard options.
• For HER2-positive breast cancer, the curative-intent setting is rapidly evolving—DESTINY-Breast05 supports adjuvant T-DXd over T-DM1 in residual disease.
• ADC plus immune checkpoint inhibitor combinations are establishing new standards in urothelial and triple-negative breast cancer; expect this paradigm to expand.
• Sequencing matters. Retrospective data suggest reduced activity of one topoisomerase 1 ADC immediately after another; prospective data are coming.
• Predictive biomarkers beyond IHC (high-sensitivity assays, molecular signatures) are needed and will increasingly guide patient selection.

Patient Perspective: What This Means for You

Antibody-drug conjugates are sometimes called “smart chemotherapy” because they use an antibody to deliver chemotherapy more directly to cancer cells. This approach has produced remarkable results in many cancer types, including breast, lung, stomach, bladder, and several others. Importantly, these are not side-effect-free treatments—patients can still experience hair loss, nausea, fatigue, low blood counts, and lung inflammation. Your care team will monitor you closely. The good news is that these drugs are being moved earlier in cancer treatment, sometimes with the goal of cure rather than just control. If your doctor recommends an ADC, ask which one, what side effects to watch for, and whether combining it with immunotherapy is an option for your specific cancer type.

Key Takeaways

Highlights

• More than 300 ADCs are in active development; 12 are FDA-approved across multiple solid tumors.
• ADCs work through targeted delivery, prolonged low-dose chemo exposure, and bystander effect—not just precision binding.
• T-DXd has redefined what is achievable in HER2-positive, HER2-low, and HER2-expressing tumors, including a tumor-agnostic indication.
• ADC plus immunotherapy combinations are setting new first-line standards (BEGONIA, ASCENT-04, EV-302).
• Sequencing, predictive biomarkers, and next-generation designs (bispecifics, dual payloads, ISACs, probody ADCs) define the near-term frontier.

Author Bio

Paolo Tarantino, MD, PhD

Paolo Tarantino is a breast medical oncologist and clinical researcher at Dana-Farber Cancer Institute and Harvard Medical School in Boston, MA. He obtained his medical degree from the University Federico II of Naples, Italy, and completed his medical oncology training at the European Institute of Oncology and the University of Milan, where he also earned a PhD in Clinical Research. His research focuses on the mechanisms of action of ADCs and the development of predictive biomarkers to optimize their use in oncology. He has authored more than 100 scientific publications and is actively involved in multiple clinical and translational studies aiming to improve the precision of ADC-based treatment. He serves as Associate Editor of ESMO Open, is a member of the ESMO CommunicationCommittee, and is a Visiting Professor at McGill University.

References and Further Reading

• Modi S, et al. Trastuzumab deruxtecan in HER2-positive metastatic breast cancer (DESTINY-Breast01/03). N Engl J Med.
• Modi S, et al. Trastuzumab deruxtecan in HER2-low metastatic breast cancer (DESTINY-Breast04/06).
• Meric-Bernstam F, et al. Tumor-agnostic T-DXd in HER2-expressing solid tumors (DESTINY-PanTumor02).
• Powles T, et al. Enfortumab vedotin plus pembrolizumab in urothelial cancer (EV-302). N Engl J Med.
• Schmid P, et al. Sacituzumab govitecan plus pembrolizumab in PD-L1+ TNBC (ASCENT-04).
• Tarantino P, et al. Real-world outcomes of treatments after T-DXd. 2024 publication.
• Binaytara: Detroit 2026 Conference Proceedings, binaytara.org.

Frequently Asked Questions (FAQs)

1. What are antibody-drug conjugates (ADCs)?

Antibody-drug conjugates (ADCs) are targeted cancer therapies that combine a monoclonal antibody with a chemotherapy drug. The antibody directs the treatment to cancer cells, allowing more precise delivery of the cytotoxic payload.

2. How do ADCs differ from traditional chemotherapy?

Unlike traditional chemotherapy, which affects both healthy and cancerous cells, ADCs aim to deliver chemotherapy directly to tumor cells. This can improve effectiveness while reducing—but not eliminating—systemic side effects.

3. What cancers are treated with ADCs?

ADCs are approved for multiple solid tumors, including breast, lung, gastric, urothelial, and gynecologic cancers. Research is ongoing to expand their use across additional cancer types.

4. Are ADCs considered chemotherapy or targeted therapy?

ADCs are often described as “targeted chemotherapy.” They combine elements of both approaches—using targeted antibodies to deliver potent chemotherapy drugs directly to cancer cells.

5. What are the common side effects of ADCs?

Common side effects include nausea, fatigue, hair loss, low blood counts (neutropenia), and lung inflammation (interstitial lung disease). Despite being targeted, ADCs can still cause systemic toxicity.

6. What is the “bystander effect” in ADC therapy?

The bystander effect occurs when the chemotherapy payload released from an ADC diffuses into nearby tumor cells—even those that may not express the target antigen—enhancing overall tumor cell killing.

7. Can ADCs be combined with immunotherapy?

Yes. ADCs are increasingly combined with immunotherapy because chemotherapy can stimulate immune responses, leading to improved outcomes in some cancers.

8. Are ADCs used as first-line cancer treatment?

While initially used in later lines of therapy, ADCs are now being studied and increasingly used in earlier treatment settings, including first-line and even curative-intent therapy.

9. What is the most advanced ADC currently available?

Trastuzumab deruxtecan (T-DXd) is one of the most advanced ADCs, showing significant benefits across multiple HER2-positive and HER2-low cancers, including tumor-agnostic indications.

10. What is the future of ADCs in cancer treatment?

The future includes next-generation ADCs such as bispecific antibodies, dual-payload designs, and improved biomarkers to better select patients and enhance treatment safety and effectiveness.